MCM
AVDL

Moore Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Moore Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100,000
Closed -$504K – 522
2020
Q3 		$504K Hold
100,000
– – 0.01% 320
2020
Q2 		$808K Buy
+100,000
New +$882K 0.02% 215

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Moore Capital Management's AVDL Position: Q4 2020 in Review

Moore Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2020, closing a stake of 100,000 shares — an estimated $504K sold.

Moore Capital Management first reported a position in AVDL in Q2 2020 and held it in 2 quarters. The position peaked at $808K in Q2 2020. 82 funds tracked by Wall St. Rank hold AVDL as of Q4 2020.

  • Moore Capital Management reported no remaining Avadel Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Moore Capital Management sold 100,000 Avadel Pharmaceuticals shares in Q4 2020, an estimated $504K.
  • Moore Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Moore Capital Management's Avadel Pharmaceuticals position peaked at $808K in Q2 2020.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2020.

Based on Moore Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.